The overall effectiveness of prophylaxis in severe haemophilia.
about
Recombinant FIXFc: a novel therapy for the royal disease?Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialOutcome measures monitoring physical function in children with haemophilia: a systematic review.Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide.International workshop on immune tolerance induction: consensus recommendations.Prophylaxis in adults with haemophilia.Identifying and overcoming barriers to prophylaxis in the management of haemophilia.Optimizing outcomes for patients with severe haemophilia A.Haemophilia A: meeting the needs of individual patients.Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience.Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia ANovel drugs to treat hemophilia.Haemophilia B: current pharmacotherapy and future directions.Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis.The role of Rixubis™ in the treatment of hemophilia B.Prevention of bleeding in hemophilia patients with high-titer inhibitors.Preliminary evaluation of altered brain microstructure in the emotion-cognition region in children with haemophilia A: a diffusional kurtosis imaging study.A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score.Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.Treatment adherence in hemophilia.Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART).Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.VERITAS-Pro: a new measure of adherence to prophylactic regimens in haemophilia.Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia.Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study.Practice patterns in haemophilia A therapy -- global progress towards optimal care.Considerations in the evaluation of haemophilia patients for short-term prophylactic therapy: a paediatric and adult case study.Haemophilia Joint Health Score in healthy adults playing sports.Hemophilia joint health score reliability study.Usefulness of a simple self-administered joint condition assessment sheet to predict the need for orthopaedic intervention in the management of haemophilic arthropathy.Manual therapy in the treatment of ankle hemophilic arthropathy. A randomized pilot study.Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.BAX326 (recombinant coagulation factor IX) for the treatment and prophylaxis of hemophilia B.Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.Joint health and functional ability in children with haemophilia who receive intensive replacement therapy.Comparison of muscle strength and in-vivo muscle morphology in young children with haemophilia and those of age-matched peers.Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
P2860
Q33968782-438A41FA-B944-465F-8FBC-9F0E1C03BF7EQ34737483-AE3DCD92-EA0C-4AC3-BE2B-F5FD25A80984Q35046841-AACECE41-9A57-4B70-99C0-61BFB0EFDF3AQ35915662-C1A57BC7-FCD4-4CAF-AD59-16951855D8C3Q36861097-8A3EB32F-4427-49EC-9DDA-0369A20A49CBQ36904925-BA82C8AC-E8F7-4338-B0F5-6BF2DA331238Q36904929-E31AA18B-9BA1-4DF9-9326-AC48ED90B11EQ36932769-78B5730D-34EE-42CB-97E2-5E68C4AF6600Q37008132-A87D2BB3-0CF0-423C-8240-E63A21FAE078Q37052161-E5D1381B-421E-49F0-9621-438DF9566D2FQ37303186-9BBAC0E5-32CA-4052-AE66-15844FB32959Q37775029-737715A5-441C-4C38-9AB7-66423811172EQ38040458-365DAF2F-1E24-479F-87D8-88001A26A3E1Q38114123-CFCE6643-65D4-4DDE-A15D-A2504F7E51F9Q38210808-FB639534-C9C3-4B46-B1DC-0AAA25CD7EE3Q38456352-E2AD2AA3-4E1A-4360-B4BC-5BBDD14C0154Q38958344-837F70AA-9F93-4301-A1B6-89C255928970Q39776012-23D94AF6-620A-45B3-81AA-A61ACAB894D0Q39834857-20463EF5-7ECE-4EB1-B16B-B781A70E854BQ42285404-13625E16-B7CB-4F1B-993D-20FA4F240B4CQ42371331-EEEF8316-5746-4FB9-9206-2471B1304B23Q42693839-408425A6-5001-4E4D-B56C-E1A017DA4542Q44051815-5D471B21-195F-4395-B510-63B75441122CQ44125442-D87978DE-67E8-400A-8F80-975D7817B8AFQ44988735-D3AAA6E3-E213-41C5-95A4-0EE3D097BB0EQ45038280-680C47E2-609D-4E3E-BB16-F4C4E5AF7D30Q45351733-356B4060-9BBF-4389-B136-165EA8B0BDFEQ45855105-0637EFF7-BF62-4937-9BB4-5630D7C2FA89Q45855111-622D22E1-5C7E-4322-892F-AA809312226FQ45857590-928C6950-E5C7-471F-B694-A5AA51D32A9FQ45861867-7CF86280-BA25-4217-ABCB-1DEFCAF77260Q45862779-9A73C7B6-2068-4973-949D-9E6190D2AEC6Q45863688-B9546A28-DFE4-46FF-9638-F8C69B82D47FQ45864939-98E809B8-CFA3-42B1-B2FA-36FAB5F72D93Q45865134-8ECCB818-17D5-42E5-8EAF-25FFE44DADBBQ45869935-370571FA-8468-46BB-89F0-7131C468199FQ45870065-5FE5F104-DF41-4481-8EC1-A999C5D852B8Q45872107-6CC53AD9-ABBE-40B0-96D5-DC6296E1F9CBQ45875265-588386EE-5A0F-4C8D-B908-663209AAAFEDQ45878007-5418B662-C548-457A-8501-AB56035C6A66
P2860
The overall effectiveness of prophylaxis in severe haemophilia.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The overall effectiveness of prophylaxis in severe haemophilia.
@ast
The overall effectiveness of prophylaxis in severe haemophilia.
@en
type
label
The overall effectiveness of prophylaxis in severe haemophilia.
@ast
The overall effectiveness of prophylaxis in severe haemophilia.
@en
prefLabel
The overall effectiveness of prophylaxis in severe haemophilia.
@ast
The overall effectiveness of prophylaxis in severe haemophilia.
@en
P2093
P2860
P1433
P1476
The overall effectiveness of prophylaxis in severe haemophilia.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2516.2003.00757.X
P577
2003-05-01T00:00:00Z